Exchange Traded Concepts LLC Has $1.15 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Exchange Traded Concepts LLC trimmed its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 44.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,298 shares of the biotechnology company’s stock after selling 13,642 shares during the period. Exchange Traded Concepts LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,148,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Marshall Wace LLP lifted its position in Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Arrowhead Pharmaceuticals by 3,142.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after purchasing an additional 2,017,489 shares in the last quarter. Norges Bank purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $30,414,000. Deerfield Management Company L.P. purchased a new stake in shares of Arrowhead Pharmaceuticals in the third quarter worth approximately $34,249,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at approximately $27,349,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $64.19, for a total value of $641,900.00. Following the sale, the insider owned 236,958 shares of the company’s stock, valued at approximately $15,210,334.02. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the completion of the transaction, the chief operating officer owned 474,908 shares in the company, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 99,657 shares of company stock valued at $6,300,153 in the last 90 days. 3.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ARWR has been the topic of several analyst reports. Bank of America lifted their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. Morgan Stanley lifted their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 7th. B. Riley Financial upped their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock opened at $61.03 on Friday. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The firm has a market cap of $8.55 billion, a PE ratio of 39.89 and a beta of 1.26. The business has a 50 day moving average of $62.43 and a 200-day moving average of $54.33. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). The business had revenue of $264.03 million during the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.39) EPS. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.